Core Viewpoint - KPB Medical-B (02216) has seen a nearly 10% increase in stock price, currently trading at 2.65 HKD, following the announcement of significant regulatory advancements for its medical devices [1] Group 1: Regulatory Approvals - KPB Medical announced that its BroncTarget® lung-targeted radiofrequency ablation system has entered the special review process by the National Medical Products Administration (NMPA) in China, indicating recognition of its core technology and clinical value [1] - The BroncTarget® system is currently undergoing confirmatory clinical trials, with 28 hospitals across the country actively recruiting participants [1] Group 2: Product Launches - The BroncAblate® Smart® lung radiofrequency ablation system has received registration approval from the Hong Kong Department of Health, marking its commercial launch as the world's first natural orifice radiofrequency ablation device for lung cancer [1] - The FleXNeedleCN single-use endoscopic aspiration biopsy needle has also been registered with the Hong Kong Department of Health [1] - The BroncTru® single-use bronchial dilation catheter has successfully obtained approval from the Indonesian Ministry of Health, marking a new breakthrough in the Southeast Asian market [1]